Atezolizumab (anti-PD-L1)

Synonyms: MPDL3280A

Catalog No.A2004 Purity:99%

Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

Atezolizumab (anti-PD-L1) Chemical Structure

Click to purchase the isotype control of Atezolizumab (anti-PD-L1)

Selleck's Atezolizumab (anti-PD-L1) has been cited by 64 publications

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 7.316mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective PD-1/PD-L1 Inhibitors

Name	Citation	PD-1/PD-L1 interaction	PD-1	PD-1/PD-L1
GS-4224	0	++++		++++
INCB086550	1	++		++
BMS-1001	0	+		+
BMS-1166	5	+++
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	12	++
BMS202	23	+
CA-170 (AUPM-170)			✔
SR 0987		✔		IL17,RORγt
Spartalizumab (anti-PD-1)		✔
Camrelizumab (anti-PD-1)		✔
AUNP-12			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description

Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.

Features

Human IgG1

Targets

hPD-L1 ^[2]
(Cell-free assay)

0.4 nM(Kd)

In Vitro
In vitro	Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models.^[1]
Cell Research:	A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations.

In Vitro

In vitro

Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models.^[1]

Cell Research:

A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations.

In Vivo
In vivo	when dual drug–loaded, core-shell nanoparticles (DLTPT) is used in combination with anti PD-L1, the tumor growth is inhibited, which induced immune response against tumor metastasis.^[2]
Animal Research	Animal Models: 4T1 tumor–bearing BALB/c mice Dosages: 2.5 or 5 mg/kg Administration: i.v. Reference:^[2]

References
[1] Della Corte CM, et al. J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. [2] He Y, et al. Sci Adv. 2021 Feb 5;7(6):eaba0776.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1380723-44-3
Isotype	Human IgG1
Source	CHO cells
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.